CJC-1295 (No DAC) + Ipamorelin (5 mg + 5 mg)

CJC-1295 (No DAC) combined with Ipamorelin is a high-purity, research-grade peptide blend widely utilized in laboratory and preclinical research focused on growth hormone signaling, receptor synergy, and endocrine pathway modulation. In this combination, CJC-1295 (No DAC) acts as a growth hormone–releasing hormone (GHRH) analog, while Ipamorelin serves as a selective ghrelin receptor agonist, providing complementary mechanisms of action.

This peptide blend offers researchers a controlled model for studying synergistic peptide-mediated signaling and growth hormone release dynamics in endocrine research.

Key Features:

• Research-grade peptide blend with strict batch-to-batch quality control

• Supplied in a 5 mg + 5 mg placeholder format for laboratory reference

• Optimized for in vitro and preclinical research applications

• Supports studies on growth hormone release, receptor interactions, and peptide synergy

• Provided with detailed handling, storage, and reconstitution instructions to maintain stability

Applications:

• Investigation of synergistic growth hormone signaling pathways

• Study of GHRH and ghrelin receptor interactions

• Preclinical research on endocrine regulation and peptide-mediated hormonal responses

Safety and Handling:
For laboratory research use only. Not intended for human consumption or clinical use. Follow standard laboratory safety protocols and store under recommended conditions to preserve peptide integrity and stability.